Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Purpose
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Conditions
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- HER2-Negative Breast Carcinoma
- Hormone Receptor-Positive Breast Carcinoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- STEP 1: REGISTRATION (SCREENING): Participants must have histologically confirmed
estrogen receptor (ER) positive and/or progesterone receptor (PR) positive (hormone
receptor positive) and HER2 negative breast cancer, as per American Society of
Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines
- NOTE: Participants with HER2 positive disease by ASCO CAP guidelines are
ineligible. HER2 negative and HER2 low or equivocal cases as per ASCO CAP
guidelines that do not receive HER2 targeted therapy are eligible
- STEP 1: REGISTRATION (SCREENING): Participants must have clinical stage II or III
breast cancer
- NOTE: Participants with inflammatory breast cancer are eligible
- NOTE: Participants with occult (i.e. undetectable) primary breast cancer with
axillary nodal involvement are not eligible, as MammaPrint testing has not been
validated on tissue obtained from an axillary lymph node
- STEP 1: REGISTRATION (SCREENING): Participants must not have metastatic disease
(i.e., must be clinically M0 or Mx) Systemic staging studies with imaging should
follow routine practice as per National Comprehensive Cancer Network (NCCN) and ASCO
guidelines
- STEP 1: REGISTRATION (SCREENING): Participants must not have locally recurrent
breast cancer
- STEP 1: REGISTRATION (SCREENING): Participants with multifocal disease in the same
breast or synchronous bilateral primary tumors are eligible, however, all tumors
that are biopsied must be hormone receptor positive and HER2 negative per ASCO CAP
guidelines and at least one of the tumors must be MammaPrint High-2. MammaPrint can
be performed sequentially on biopsies as it is sufficient to have MammaPrint High 2
status on at least one of the lesions
- NOTE: Biopsy of multiple lesions in the same breast is not required if the
clinical presentation is consistent with a single disease process that is
multifocal in nature. However, if there is clinical suspicion of two distinct
primary breast malignancies, additional biopsies should be pursued
- STEP 1: REGISTRATION (SCREENING): Participants must have either adequate tissue
available to submit on-study or a prior known MammaPrint Index Score that is MP2
status
- Submitting tissue for on-study MammaPrint testing:
- Participants must have a minimum of ten, unstained formalin-fixed
paraffin-embedded (FFPE) slides (4-5 micron thickness) available from
initial tumor biopsy for MammaPrint assessment
- NOTE: Participants must agree to have this tissue submitted to
Agendia for MammaPrint Index Scoring and to have subsequent results
disclosed to Southwest Oncology Group (SWOG) Cancer Research Network
OR
- Submitting prior known MammaPrint Index Score:
- If a MammaPrint Index Score report from within the last 12 weeks is
already known and is MP2 status, the participant must be registered to
Step 2 immediately following Step 1 registration provided they meet all
other criteria. MP2 status is defined as a MammaPrint Index score between
negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and
negative 0.57) tested from initial tumor biopsy
- NOTE: Participants must agree to have their commercial MammaPrint
Index Score disclosed to SWOG Cancer Research Network
- NOTE: Participants with prior known MammaPrint result that is not MP2
status should not be enrolled to either step of this study
- NOTE: Participants enrolling with known MP2 status (i.e. MP already
obtained as routine care) must only sign the treatment informed
consent form. Screening consent is not required when MP2 status is
known prior to study enrollment
- STEP 1: REGISTRATION (SCREENING): Participants must not have received any prior
treatment for their current breast cancer, including chemotherapy, immunotherapy,
biologic or hormonal therapy, and must be candidates for doxorubicin, paclitaxel,
and durvalumab therapy
- STEP 1: REGISTRATION (SCREENING): Participants must be >= 18 years old at the time
of registration
- STEP 1: REGISTRATION (SCREENING): Participants must have body weight > 30 kg
- STEP 1: REGISTRATION (SCREENING): Participants must have Zubrod Performance Status
of 0-2
- STEP 1: REGISTRATION (SCREENING): Participants with a prior or concurrent malignancy
whose natural history or treatment does not have the potential to interfere with the
safety or efficacy assessment of the investigational regimen are eligible for this
trial
- STEP 1: REGISTRATION (SCREENING): Participant must not have medical
contraindications to receiving immunotherapy, including history of non-infectious
pneumonitis that required steroids or active autoimmune disease that has required
systemic treatment with disease modifying agents, corticosteroids or
immunosuppressive drugs in the past two years. Replacement therapy (e.g. thyroxine
for pre-existing hypothyroidism, insulin for type I diabetes mellitus, or
physiologic corticosteroid replacement therapy for adrenal or pituitary
insufficiency, etc.) is not considered a form of systemic treatment. Intra-articular
steroid injections are allowed
- STEP 1: REGISTRATION (SCREENING): NOTE: As a part of the Oncology Patient Enrollment
Network (OPEN) registration process the treating institution's identity is provided
in order to ensure that the current (within 365 days) date of institutional review
board approval for this study has been entered in the system
- Participants must be informed of the investigational nature of this study and
must sign and give informed consent in accordance with institutional and
federal guidelines
- For participants with impaired decision-making capabilities, legally authorized
representatives may sign and give informed consent on behalf of study
participants in accordance with applicable federal, local, and Central
Institutional Review Board (CIRB) regulations
- STEP 2: RANDOMIZATION: Participants must have met all eligibility criteria for Step
1 Registration
- STEP 2: RANDOMIZATION: Participants must have MammaPrint High Risk 2 result
- For participants submitting tissue for on-study MammaPrint testing:
- Participants must be registered to Step 2: Randomization within 84
calendar days (12 weeks) after receiving an MP2 status from the MammaPrint
Index score. MP2 status is defined as a MammaPrint Index score between
negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and
negative 0.57) from initial tumor biopsy OR
- Submitting commercial MammaPrint Index Score:
- If a MammaPrint Index Score report from within the last 12 weeks is
already known and is MP2 status, the participant must be registered to
Step 2 immediately following Step 1 registration provided they meet all
other criteria. MP2 status is defined as a MammaPrint Index score between
negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and
negative 0.57) tested from initial tumor biopsy
- NOTE: Participants without a MammaPrint High-Risk 2 score must not be
registered to Step 2 Randomization
- STEP 2: RANDOMIZATION: Participants must not have received live vaccines within 28
days prior to study Step 2: Randomization. Examples of live vaccines include, but
are not limited to, the following: measles, mumps, rubella, chicken pox, shingles,
yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine.
Seasonal influenza vaccines and coronavirus disease 2019 (COVID-19) vaccines are
allowed; however, intranasal influenza vaccines (e.g. Flu-Mist) are live attenuated
vaccines, and are not allowed
- STEP 2: RANDOMIZATION: Participants must not be planning to receive any concurrent
non-protocol directed chemotherapy, immunotherapy, biologic or hormonal therapy for
cancer treatment while receiving treatment on this study
- STEP 2: RANDOMIZATION: Participant must have Zubrod Performance Status of 0-2
- STEP 2: RANDOMIZATION: Participants must not have a history of (non-infectious)
pneumonitis that required steroids or evidence of active pneumonitis within two
years prior to Step 2: Randomization
- STEP 2: RANDOMIZATION: Participants must not have active autoimmune disease that has
required systemic treatment in the past two years (i.e., with use of disease
modifying agents, corticosteroids or immunosuppressive drugs) prior to Step 2:
Randomization. Replacement therapy (e.g. thyroxine for pre-existing hypothyroidism,
insulin for type I diabetes mellitus, or physiologic corticosteroid replacement
therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of
systemic treatment. Intra-articular steroid injections are allowed
- STEP 2: RANDOMIZATION: Participant must have a complete medical history and physical
exam within 28 days prior to Step 2: Randomization
- STEP 2: RANDOMIZATION: Leukocytes >= 3 x 10^3/uL (within 28 days prior to Step 2:
Randomization)
- STEP 2: RANDOMIZATION: Absolute neutrophil count >= 1.5 x 10^3/uL (within 28 days
prior to Step 2: Randomization)
- STEP 2: RANDOMIZATION: Platelets >= 100 x 10^3/uL (within 28 days prior to Step 2:
Randomization)
- STEP 2: RANDOMIZATION: Total bilirubin =< institutional upper limit of normal (ULN)
unless history of Gilbert's disease. Participants with history of Gilbert's disease
must have total bilirubin =< 5 x institutional ULN (within 28 days prior to Step 2:
Randomization)
- STEP 2: RANDOMIZATION: Aspartate aminotransferase (AST)/alanine aminotransferase
(ALT) =< 3 × institutional ULN (within 28 days prior to Step 2: Randomization)
- STEP 2: RANDOMIZATION: Participants must have a calculated creatinine clearance >=
50 mL/min using the Cockcroft-Gault Formula. This specimen must have been drawn and
processed within 28 days prior to Step 2: Randomization
- STEP 2: RANDOMIZATION: Participants must have adequate cardiac function.
Participants with known history or current symptoms of cardiac disease, or history
of treatment with cardiotoxic agents, must have a clinical risk assessment of
cardiac function using the New York Heart Association Functional Classification. To
be eligible for this trial, participants must be class 2B or better
- STEP 2: RANDOMIZATION: Participants must not have uncontrolled diabetes defined as
hemoglobin A1c of 9.0% or greater, within 28 days prior to Step 2: Randomization
- STEP 2: RANDOMIZATION: Participants with history of human immunodeficiency virus
(HIV)-infection must be on effective anti-retroviral therapy at registration and
have an undetectable viral load on the most recent test results obtained within 6
months prior to Step 2: Randomization
- STEP 2: RANDOMIZATION: Participants with history of chronic hepatitis B virus (HBV)
infection must have undetectable HBV viral load on the most recent test results
obtained while on suppressive therapy within 6 months prior to Step 2:
Randomization, if indicated
- STEP 2: RANDOMIZATION: Participants with a history of hepatitis C virus (HCV)
infection must have been treated and cured. Participants currently being treated for
HCV infection must have undetectable HCV viral load on the most recent test results
obtained within 6 months prior to Step 2: Randomization, if indicated
- STEP 2: RANDOMIZATION: Participants must not be pregnant or nursing. Individuals who
are of reproductive potential must have agreed to use an effective contraceptive
method during protocol therapy and for 6 months following completion of protocol
therapy with details provided as a part of the consent process and must have a
negative pregnancy test at screening. A person who has had menses at any time in the
preceding 12 consecutive months or who has semen likely to contain sperm is
considered to be of "reproductive potential." In addition to routine contraceptive
methods, "effective contraception" also includes refraining from sexual activity
that might result in pregnancy and surgery intended to prevent pregnancy (or with a
side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy,
bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in
the semen. Participants should not breastfeed during protocol therapy and for 6
months following completion of protocol therapy
- STEP 2: RANDOMIZATION: Participants must be offered the opportunity to participate
in specimen banking. With participant consent, specimens must be collected and
submitted via the SWOG Specimen Tracking System
- STEP 2: RANDOMIZATION: Participants who can complete questionnaires in English, or
Spanish must be offered the opportunity to participate in the Quality of Life study
- STEP 2: RANDOMIZATION: NOTE: As a part of the OPEN registration process the treating
institution's identity is provided in order to ensure that the current (within 365
days) date of institutional review board approval for this study has been entered in
the system
- STEP 2: RANDOMIZATION: Participants must be informed of the investigational nature
of this study and must sign and give informed consent in accordance with
institutional and federal guidelines
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Sequential Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Step 1 (MammaPrint testing) |
Patients without a known MP2 score undergo MammaPrint testing on a previously-collected tissue sample. Patients with MP2 score proceed to STEP 2 |
|
|
Active Comparator Step 2, Arm 1 (chemotherapy) |
Patients receive paclitaxel IV on days 1 and 8 of each cycle. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxorubicin IV and cyclophosphamide IV on day 1 of each cycle. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo mammography during screening (STEP 1). Patients have the option to also undergo collection of tumor tissue during initial biopsy (STEP 1) and at SOC surgery and undergo collection of blood samples throughout the study. |
|
|
Experimental Step 2, Arm 2 (chemotherapy, durvalumab) |
Patients receive paclitaxel IV on days 1 and 8 of each cycle and durvalumab IV over 60 minutes on day 1 of cycles 1, 3, and 5. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxorubicin IV and cyclophosphamide IV on day 1 of each cycle, and durvalumab IV over 60 minutes on day 1 of cycles 7 and 9. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo mammography during screening (STEP 1). Patients have the option to also undergo collection of tumor tissue during initial biopsy (STEP 1) and at SOC surgery and undergo collection of blood samples throughout the study. |
|
Recruiting Locations
Birmingham, Alabama 35233
Anchorage, Alaska 99508
Tucson, Arizona 85704
Site Public Contact
520-694-8900
Tucson, Arizona 85719
Tucson, Arizona 85719
Fort Smith, Arkansas 72903
Site Public Contact
800-378-9373
Jonesboro, Arkansas 72401
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Auburn, California 95602
Bakersfield, California 93301
Site Public Contact
661-323-4673
Berkeley, California 94704
Beverly Hills, California 90211
Duarte, California 91010
Fremont, California 94538
Irvine, California 92612
Irvine, California 92618
Site Public Contact
877-467-3411
Lancaster, California 93534
Loma Linda, California 92354
Site Public Contact
909-558-4050
Long Beach, California 90813
Site Public Contact
877-467-3411
Los Angeles, California 90025
Los Angeles, California 90048
Modesto, California 95355
Newport Beach, California 92660
Site Public Contact
877-467-3411
Orange, California 92868
Palm Springs, California 92262
Site Public Contact
760-416-4730
Palo Alto, California 94301
Pasadena, California 91105
Site Public Contact
626-535-2420
Roseville, California 95661
Sacramento, California 95816
San Francisco, California 94115
San Mateo, California 94401
Santa Cruz, California 95065
Santa Rosa, California 95403
Site Public Contact
707-521-3830
Santa Rosa, California 95403
Santa Rosa, California 95405
Site Public Contact
707-521-3830
South Pasadena, California 91030
Sunnyvale, California 94086
Tarzana, California 91356
Site Public Contact
818-981-3818
Torrance, California 90503
Site Public Contact
877-467-3411
Torrance, California 90505
Upland, California 91786
Vallejo, California 94589
Yorba Linda, California 92886
Aurora, Colorado 80045
Site Public Contact
720-848-0650
Edwards, Colorado 81632
Site Public Contact
970-569-7429
Fort Collins, Colorado 80524
Site Public Contact
970-297-6150
Fort Collins, Colorado 80528
Highlands Ranch, Colorado 80129
Site Public Contact
720-848-0650
Lone Tree, Colorado 80124
Loveland, Colorado 80538
Site Public Contact
970-203-7083
Derby, Connecticut 06418
Fairfield, Connecticut 06824
Glastonbury, Connecticut 06033
Greenwich, Connecticut 06830
Guilford, Connecticut 06437
Hartford, Connecticut 06105
New Haven, Connecticut 06520
North Haven, Connecticut 06473
Stamford, Connecticut 06902
Torrington, Connecticut 06790
Trumbull, Connecticut 06611
Waterbury, Connecticut 06708
Waterford, Connecticut 06385
Millville, Delaware 19967
Newark, Delaware 19713
Newark, Delaware 19713
Rehoboth Beach, Delaware 19971
Washington D.C., District of Columbia 20016
Aventura, Florida 33180
Bonita Springs, Florida 34135
Clearwater, Florida 33756
Site Public Contact
855-314-8646
Fort Myers, Florida 33905
Hollywood, Florida 33021
Miami Beach, Florida 33140
Pembroke Pines, Florida 33028
Site Public Contact
954-265-4325
Safety Harbor, Florida 34695
Tampa, Florida 33607
Winter Haven, Florida 33881
Atlanta, Georgia 30303
Site Public Contact
404-778-1868
Atlanta, Georgia 30308
Site Public Contact
888-946-7447
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Atlanta, Georgia 30342
Site Public Contact
404-851-7115
Decatur, Georgia 30033
Johns Creek, Georgia 30097
Savannah, Georgia 31405
Boise, Idaho 83706
Boise, Idaho 83712
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Fruitland, Idaho 83619
Meridian, Idaho 83642
Nampa, Idaho 83687
Nampa, Idaho 83687
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Aurora, Illinois 60506
Barrington, Illinois 60010
Site Public Contact
847-842-4847
Bloomington, Illinois 61704
Canton, Illinois 61520
Carterville, Illinois 62918
Carthage, Illinois 62321
Chicago, Illinois 60608
Chicago, Illinois 60611
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Chicago, Illinois 60657
Site Public Contact
773-296-5360
Crystal Lake, Illinois 60014
Danville, Illinois 61832
Decatur, Illinois 62526
Decatur, Illinois 62526
DeKalb, Illinois 60115
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Downers Grove, Illinois 60515
Effingham, Illinois 62401
Effingham, Illinois 62401
Elgin, Illinois 60123
Site Public Contact
847-429-2907
Eureka, Illinois 61530
Galesburg, Illinois 61401
Geneva, Illinois 60134
Glenview, Illinois 60026
Site Public Contact
312-695-1102
Grayslake, Illinois 60030
Site Public Contact
312-695-1102
Hazel Crest, Illinois 60429
Site Public Contact
708-799-9995
Kewanee, Illinois 61443
Lake Forest, Illinois 60045
Libertyville, Illinois 60048
Libertyville, Illinois 60048
Macomb, Illinois 61455
Mattoon, Illinois 61938
Maywood, Illinois 60153
Site Public Contact
708-226-4357
Moline, Illinois 61265
Site Public Contact
309-779-2000
Mount Vernon, Illinois 62864
Normal, Illinois 61761
Normal, Illinois 61761
O'Fallon, Illinois 62269
Oak Brook, Illinois 60523
Oak Lawn, Illinois 60453-2699
Site Public Contact
800-323-8622
Orland Park, Illinois 60462
Ottawa, Illinois 61350
Park Ridge, Illinois 60068
Site Public Contact
847-384-3621
Pekin, Illinois 61554
Peoria, Illinois 61615
Peru, Illinois 61354
Princeton, Illinois 61356
Rockford, Illinois 61108
Site Public Contact
815-227-2633
Rockford, Illinois 61114
Shiloh, Illinois 62269
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Urbana, Illinois 61801
Warrenville, Illinois 60555
Washington, Illinois 61571
Crown Point, Indiana 46307
Dyer, Indiana 46311
Site Public Contact
219-924-8178
Hobart, Indiana 46342
Site Public Contact
219-947-1795
Hobart, Indiana 46342
Indianapolis, Indiana 46312
Munster, Indiana 46321
Site Public Contact
219-836-3349
Munster, Indiana 46321
Valparaiso, Indiana 46383
Ankeny, Iowa 50023
Site Public Contact
515-241-3305
Carroll, Iowa 51401
Cedar Rapids, Iowa 52403
Site Public Contact
319-365-4673
Cedar Rapids, Iowa 52403
Site Public Contact
319-363-2690
Clive, Iowa 50325
Site Public Contact
515-241-3305
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-282-2200
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Fort Dodge, Iowa 50501
Waukee, Iowa 50263
Site Public Contact
515-241-3305
Hays, Kansas 67601
Site Public Contact
785-623-5774
Kansas City, Kansas 66160
Lawrence, Kansas 66044
Olathe, Kansas 66061
Overland Park, Kansas 66210
Overland Park, Kansas 66211
Salina, Kansas 67401
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Westwood, Kansas 66205
Corbin, Kentucky 40701
Site Public Contact
859-523-1934
Lexington, Kentucky 40509
Lexington, Kentucky 40536
Site Public Contact
859-257-3379
Monroe, Louisiana 71202
New Orleans, Louisiana 70112
New Orleans, Louisiana 70115
Shreveport, Louisiana 71103
Shreveport, Louisiana 71106
Site Public Contact
318-813-1406
Aberdeen, Maryland 21001
Baltimore, Maryland 21201
Site Public Contact
800-888-8823
Baltimore, Maryland 21202
Baltimore, Maryland 21215
Site Public Contact
410-601-9083
Baltimore, Maryland 21287
Bel Air, Maryland 21014
Site Public Contact
443-643-3010
Cumberland, Maryland 21502
Site Public Contact
240-964-1400
Glen Burnie, Maryland 21061
Site Public Contact
410-553-8100
Westminster, Maryland 21157
Site Public Contact
410-871-6400
Beverly, Massachusetts 01915
Site Public Contact
978-922-3000
Boston, Massachusetts 02111
Burlington, Massachusetts 01805
Gloucester, Massachusetts 01930
Site Public Contact
978-283-4000
Peabody, Massachusetts 01960
Ann Arbor, Michigan 48106
Ann Arbor, Michigan 48109
Battle Creek, Michigan 49017
Brighton, Michigan 48114
Brighton, Michigan 48114
Brighton, Michigan 48116
Site Public Contact
800-865-1125
Brownstown, Michigan 48183
Canton, Michigan 48188
Canton, Michigan 48188
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Clinton Township, Michigan 48038
Dearborn, Michigan 48124
Site Public Contact
248-551-7695
Dearborn, Michigan 48126
Detroit, Michigan 48201
Detroit, Michigan 48202
Detroit, Michigan 48236
East China Township, Michigan 48054
Escanaba, Michigan 49829
Farmington Hills, Michigan 48334
Farmington Hills, Michigan 48336
Site Public Contact
248-551-7695
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Grand Rapids, Michigan 49503
Grosse Pointe Woods, Michigan 48236
Jackson, Michigan 49201
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Lansing, Michigan 48910
Lansing, Michigan 48912
Livonia, Michigan 48154
Macomb, Michigan 48044
Niles, Michigan 49120
Site Public Contact
616-391-1230
Novi, Michigan 48374
Novi, Michigan 48377
Pontiac, Michigan 48341
Reed City, Michigan 49677
Royal Oak, Michigan 48073
Site Public Contact
248-551-7695
Saginaw, Michigan 48601
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Southfield, Michigan 48075
Tawas City, Michigan 48764
Traverse City, Michigan 49684
Troy, Michigan 48085
Site Public Contact
248-551-7695
Warren, Michigan 48093
Warren, Michigan 48093
West Bloomfield, Michigan 48322
Wyoming, Michigan 49519
Ypsilanti, Michigan 48106
Ypsilanti, Michigan 48197
Brainerd, Minnesota 56401
Burnsville, Minnesota 55337
Chaska, Minnesota 55318
Coon Rapids, Minnesota 55433
Deer River, Minnesota 56636
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Edina, Minnesota 55435
Edina, Minnesota 55435
Hibbing, Minnesota 55746
Site Public Contact
218-786-3308
Maplewood, Minnesota 55109
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55415
Robbinsdale, Minnesota 55422
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Sandstone, Minnesota 55072
Shakopee, Minnesota 55379
Stillwater, Minnesota 55082
Virginia, Minnesota 55792
Waconia, Minnesota 55387
Woodbury, Minnesota 55125
Columbus, Mississippi 39705
Grenada, Mississippi 38901
New Albany, Mississippi 38652
Oxford, Mississippi 38655
Southhaven, Mississippi 38671
Ballwin, Missouri 63011
Site Public Contact
888-446-3729
Cape Girardeau, Missouri 63703
City of Saint Peters, Missouri 63376
Creve Coeur, Missouri 63141
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Kansas City, Missouri 64108
Site Public Contact
816-404-4375
Kansas City, Missouri 64116
Site Public Contact
913-588-3671
Kansas City, Missouri 64154
Lee's Summit, Missouri 64064
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Springfield, Missouri 65807
Site Public Contact
417-269-4520
St Louis, Missouri 63110
St Louis, Missouri 63128
St Louis, Missouri 63129
St Louis, Missouri 63131
Site Public Contact
314-996-5569
St Louis, Missouri 63136
St Louis, Missouri 63141
Site Public Contact
314-251-7066
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Anaconda, Montana 59711
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Missoula, Montana 59804
Las Vegas, Nevada 89102
Las Vegas, Nevada 89183
Reno, Nevada 89502
Lebanon, New Hampshire 03756
Elizabeth, New Jersey 07207
Site Public Contact
908-994-8000
Hackettstown, New Jersey 07840
Site Public Contact
973-971-5990
Hamilton, New Jersey 08690
Site Public Contact
609-631-6946
Jersey City, New Jersey 07302
Lakewood, New Jersey 08701
Long Branch, New Jersey 07740
Morristown, New Jersey 07960
Site Public Contact
973-971-5900
New Brunswick, New Jersey 08903
Site Public Contact
732-235-7356
Newark, New Jersey 07101
Site Public Contact
732-235-7356
Newark, New Jersey 07112
Newton, New Jersey 07860
Site Public Contact
973-971-5990
Pompton, New Jersey 07444
Site Public Contact
973-971-5990
Somerville, New Jersey 08876
Summit, New Jersey 07902
Site Public Contact
908-522-2043
Toms River, New Jersey 08755
Brooklyn, New York 11220
East Hills, New York 11548
Mineola, New York 11501
Mount Kisco, New York 10549
New York, New York 10011
New York, New York 10016
New York, New York 10029
New York, New York 10065
Site Public Contact
212-434-4460
New York, New York 10075
Site Public Contact
516-734-8896
Oswego, New York 13126
Sleepy Hollow, New York 10591
Site Public Contact
914-366-1600
Southampton, New York 11968
Site Public Contact
631-638-7400
Staten Island, New York 10305
Site Public Contact
718-226-8888
Stony Brook, New York 11794
Site Public Contact
800-862-2215
Syracuse, New York 13210
Site Public Contact
315-464-5476
Syracuse, New York 13215
Site Public Contact
315-464-5476
Verona, New York 13478
West Islip, New York 11795
Site Public Contact
516-326-7514
White Plains, New York 10601
Cary, North Carolina 27518
Chapel Hill, North Carolina 27599
Clinton, North Carolina 28328
Garner, North Carolina 27529
Goldsboro, North Carolina 27534
Jacksonville, North Carolina 28546
Raleigh, North Carolina 27607
Raleigh, North Carolina 27614
Fargo, North Dakota 58103
Centerville, Ohio 45459
Cleveland, Ohio 44109
Columbus, Ohio 43210
Columbus, Ohio 43214
Columbus, Ohio 43214
Columbus, Ohio 43215
Columbus, Ohio 43228
Dayton, Ohio 45409
Dayton, Ohio 45409
Site Public Contact
937-276-8320
Dayton, Ohio 45415
Delaware, Ohio 43015
Delaware, Ohio 43015
Dublin, Ohio 43016
Dublin, Ohio 43016
Franklin, Ohio 45005-1066
Greenville, Ohio 45331
Site Public Contact
937-569-7515
Mansfield, Ohio 44903
Marion, Ohio 43302
Pickerington, Ohio 43147
Sylvania, Ohio 43560
Troy, Ohio 45373
Westerville, Ohio 43082
Oklahoma City, Oklahoma 73104
Oklahoma City, Oklahoma 73120
Site Public Contact
405-752-3402
Bend, Oregon 97701
Gresham, Oregon 97030
Site Public Contact
503-413-2150
Hood River, Oregon 97031
Newberg, Oregon 97132
Ontario, Oregon 97914
Oregon City, Oregon 97045
Portland, Oregon 97210
Portland, Oregon 97213
Portland, Oregon 97225
Tualatin, Oregon 97062
Site Public Contact
503-413-1742
Allentown, Pennsylvania 18103
Allentown, Pennsylvania 18104
Site Public Contact
610-776-4714
Beaver, Pennsylvania 15009
Bethlehem, Pennsylvania 18015
Site Public Contact
484-503-4151
Bethlehem, Pennsylvania 18017
Bryn Mawr, Pennsylvania 19010
Butler, Pennsylvania 16001
Cranberry Township, Pennsylvania 16066
Danville, Pennsylvania 17822
Dickson City, Pennsylvania 18519
East Stroudsburg, Pennsylvania 18301
Easton, Pennsylvania 18045
Erie, Pennsylvania 16505
Erie, Pennsylvania 16544
Site Public Contact
814-452-5000
Greensburg, Pennsylvania 15601
Site Public Contact
724-838-1900
Harrisburg, Pennsylvania 17109
Hazleton, Pennsylvania 18201
Indiana, Pennsylvania 15701
Jefferson Hills, Pennsylvania 15025
Johnstown, Pennsylvania 15901
Site Public Contact
814-534-4724
Lewisburg, Pennsylvania 17837
Meadville, Pennsylvania 16335
Mechanicsburg, Pennsylvania 17050
Media, Pennsylvania 19063
Monroeville, Pennsylvania 15146
Site Public Contact
412-858-7746
Monroeville, Pennsylvania 15146
Moon Township, Pennsylvania 15108
N. Huntingdon, Pennsylvania 15642
Natrona Heights, Pennsylvania 15065
Site Public Contact
724-230-3030
Paoli, Pennsylvania 19301
Pittsburgh, Pennsylvania 15212
Site Public Contact
877-284-2000
Pittsburgh, Pennsylvania 15213
Site Public Contact
412-647-2811
Pittsburgh, Pennsylvania 15215
Site Public Contact
412-784-4900
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-647-8073
Pittsburgh, Pennsylvania 15237
Site Public Contact
412-367-6454
Pittsburgh, Pennsylvania 15243
Site Public Contact
412-502-3920
Quakertown, Pennsylvania 18951
Site Public Contact
610-776-4714
Scranton, Pennsylvania 18510
Seneca, Pennsylvania 16346
Site Public Contact
814-676-7900
Stroudsburg, Pennsylvania 18360
Washington, Pennsylvania 15301
West Mifflin, Pennsylvania 15122
Site Public Contact
412-653-8100
Wexford, Pennsylvania 15090
Wilkes-Barre, Pennsylvania 18711
Williamsport, Pennsylvania 17754
Wynnewood, Pennsylvania 19096
York, Pennsylvania 17408
Site Public Contact
717-724-6760
Providence, Rhode Island 02905
Site Public Contact
401-274-1122
Westerly, Rhode Island 02891
Bluffton, South Carolina 29910
Boiling Springs, South Carolina 29316
Charleston, South Carolina 29401
Charleston, South Carolina 29403
Charleston, South Carolina 29414
Charleston, South Carolina 29414
Charleston, South Carolina 29425
Easley, South Carolina 29640
Georgetown, South Carolina 29440
Greenville, South Carolina 29605
Greenville, South Carolina 29605
Greenville, South Carolina 29605
Greenville, South Carolina 29615
Greer, South Carolina 29650
Hilton Head Island, South Carolina 29926-3827
Seneca, South Carolina 29672
Collierville, Tennessee 38017
Knoxville, Tennessee 37916
Site Public Contact
865-331-1812
Knoxville, Tennessee 37932
Site Public Contact
865-331-1812
Memphis, Tennessee 38120
Oak Ridge, Tennessee 37830
Site Public Contact
865-331-1812
Conroe, Texas 77384
Houston, Texas 77030
Houston, Texas 77030
Site Public Contact
713-873-2000
Houston, Texas 77030
Houston, Texas 77079
League City, Texas 77573
San Antonio, Texas 78229
Sugar Land, Texas 77478
Fredericksburg, Virginia 22408
Mechanicsville, Virginia 23116
Midlothian, Virginia 23114
Richmond, Virginia 23226
Richmond, Virginia 23229
Richmond, Virginia 23235
Richmond, Virginia 23298
South Hill, Virginia 23970
Edmonds, Washington 98026
Issaquah, Washington 98029
Kennewick, Washington 99336
Lacey, Washington 98503
Seattle, Washington 98122
Tacoma, Washington 98405
Vancouver, Washington 98684
Vancouver, Washington 98686
Site Public Contact
503-413-2150
Charleston, West Virginia 25304
Site Public Contact
304-388-9944
Morgantown, West Virginia 26506
Appleton, Wisconsin 54911
Ashland, Wisconsin 54806
Burlington, Wisconsin 53105
Cudahy, Wisconsin 53110
Eau Claire, Wisconsin 54701
Germantown, Wisconsin 53022
Grafton, Wisconsin 53024
Green Bay, Wisconsin 54301
Site Public Contact
920-435-8326
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
Green Bay, Wisconsin 54311
Janesville, Wisconsin 53548
Kenosha, Wisconsin 53142
Madison, Wisconsin 53718
Madison, Wisconsin 53792
Marinette, Wisconsin 54143
Marshfield, Wisconsin 54449
Menomonee Falls, Wisconsin 53051
Site Public Contact
262-257-5100
Milwaukee, Wisconsin 53209
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Milwaukee, Wisconsin 53233
Minocqua, Wisconsin 54548
Neenah, Wisconsin 54956
Oak Creek, Wisconsin 53154
Site Public Contact
414-805-0505
Oconto Falls, Wisconsin 54154
Oshkosh, Wisconsin 54904
Racine, Wisconsin 53406
Rice Lake, Wisconsin 54868
Sheboygan, Wisconsin 53081
Sheboygan, Wisconsin 53081
Spooner, Wisconsin 54801
Stevens Point, Wisconsin 54482
Sturgeon Bay, Wisconsin 54235-1495
Summit, Wisconsin 53066
Two Rivers, Wisconsin 54241
Wauwatosa, Wisconsin 53226
West Allis, Wisconsin 53227
West Bend, Wisconsin 53095
Site Public Contact
414-805-0505
Weston, Wisconsin 54476
San Juan, Puerto Rico 00927
San Juan, Puerto Rico 00927
More Details
- NCT ID
- NCT06058377
- Status
- Recruiting
- Sponsor
- National Cancer Institute (NCI)
Detailed Description
PRIMARY OBJECTIVE: I. To compare breast cancer event-free survival between participants randomized to standard of care neoadjuvant chemotherapy alone versus standard of care neoadjuvant chemotherapy concurrent with durvalumab. SECONDARY OBJECTIVES: I. To compare pathologic complete response rates (ypT0/is, ypN0) in participants randomized to standard of care chemotherapy alone versus (vs.) standard of care neoadjuvant chemotherapy concurrent with durvalumab. II. To compare residual cancer burden distribution between participants randomized to standard of care neoadjuvant chemotherapy vs. standard of care neoadjuvant chemotherapy concurrent with durvalumab. III. To compare distant relapse-free survival between participants randomized to standard of care neoadjuvant chemotherapy vs. standard of care neoadjuvant chemotherapy concurrent with durvalumab. IV. To compare overall survival between participants randomized to standard of care neoadjuvant chemotherapy vs. standard of care neoadjuvant chemotherapy concurrent with durvalumab. V. To compare the frequency and severity of toxicities between participants randomized to standard of care neoadjuvant chemotherapy vs. standard of care neoadjuvant chemotherapy concurrent with durvalumab among those who initiate the assigned treatment. PRIMARY QUALITY OF LIFE (QOL) OBJECTIVES: I. To compare the change in fatigue (Patient Reported Outcomes Measurement Information System [PROMIS] Fatigue) experienced by participants randomized to neoadjuvant durvalumab plus chemotherapy vs. participants randomized to chemotherapy alone at completion of active treatment (at 20 weeks from baseline). II. To compare the change in global physical health (PROMIS Global Health) experienced by participants randomized to neoadjuvant durvalumab plus chemotherapy vs participants randomized to chemotherapy alone at completion of active treatment (at 20 weeks from baseline). SECONDARY QOL OBJECTIVES: I. To compare the change in fatigue and global physical health experienced by participants randomized to neoadjuvant durvalumab plus chemotherapy vs participants randomized to chemotherapy alone during treatment (at 12 weeks from baseline). II. To compare the changes in global physical health and fatigue subsequent to treatment (at years 1 and 2) between the two randomized study arms. III. To compare the changes in global mental health (PROMIS Global Health) during active treatment (weeks 12, 20) and subsequent to treatment (at years 1 and 2) between the two randomized study arms. IV. To compare the severity and frequency of treatment-related symptoms using Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) items (diarrhea, nausea, cough, shortness of breath, rash, and musculoskeletal pain) over time experienced by participants receiving neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone. BANKING OBJECTIVE: I. To bank specimens for future correlative studies. OUTLINE: STEP 1: Patients without a known MP2 score undergo MammaPrint testing on a previously-collected tissue sample. Patients with MP2 score proceed to STEP 2. STEP 2: Patients are randomized to 1 of 2 arms. ARM 1: Patients receive paclitaxel intravenously (IV) on days 1 and 8 of each cycle. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxorubicin IV and cyclophosphamide IV on day 1 of each cycle. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity. ARM 2: Patients receive paclitaxel IV on days 1 and 8 of each cycle and durvalumab IV over 60 minutes on day 1 of cycles 1, 3, and 5. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxorubicin IV and cyclophosphamide IV on day 1 of each cycle, and durvalumab IV over 60 minutes on day 1 of cycles 7 and 9. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity. All patients also undergo mammography during screening (STEP 1). Patients have the option to also undergo collection of tumor tissue during initial biopsy (STEP 1) and at standard of care (SOC) surgery and undergo collection of blood samples throughout the study. After completion of study treatment, patients are followed until death or 10 years, whichever occurs first.